Jensen R T, Pandol S J, Collen M J, Raufman J P, Gardner J D
J Clin Gastroenterol. 1983;5 Suppl 1:123-31. doi: 10.1097/00004836-198312001-00012.
In the last 10 years, the basis for the diagnosis and treatment of gastric hypersecretion in Zollinger-Ellison syndrome has changed dramatically. The diagnostic criteria have changed because gastrin hypersecretion by a non-beta islet tumor is now known to be responsible for gastric hypersecretion, and gastrin radioimmunoassays are now widely available. The treatment of the gastric hypersecretion in Zollinger-Ellison syndrome has changed since development of histamine H2-receptor antagonists and the demonstration that gastric acid secretion can be controlled medically in most patients, obviating routine total gastrectomy. In this paper, we review currently available and newer antisecretory drugs, the results of long-term medical treatment, potential problem areas, and our current approach to controlling gastric hypersecretion in patients with Zollinger-Ellison syndrome.
在过去10年中，卓-艾综合征胃分泌过多的诊断和治疗基础发生了巨大变化。诊断标准发生了改变，因为现在已知非β胰岛细胞瘤分泌过多胃泌素是导致胃分泌过多的原因，而且胃泌素放射免疫测定法现已广泛应用。自从组胺H2受体拮抗剂研制出来以及证明大多数患者的胃酸分泌可以通过药物控制从而避免常规全胃切除术后，卓-艾综合征胃分泌过多的治疗也发生了变化。在本文中，我们综述了目前可用的和更新的抗分泌药物、长期药物治疗的结果、潜在的问题领域以及我们目前控制卓-艾综合征患者胃分泌过多的方法。
